Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.56 |
| ▸ | REN | P00797 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802212 | 0.96 | ACE (0.52) | ACERENOPRK1 | |
| SCHEMBL29801920 | 0.96 | ACE (0.52) | ACERENOPRK1 | |
| SCHEMBL29802055 | 0.96 | ACE (0.52) | ACERENOPRK1 | |
| SCHEMBL29801883 | 0.94 | ACE (0.51) | ACERENOPRK1 | |
| SCHEMBL29409430 | 0.94 | OPRK1 (0.55) | ACEOPRK1 | |
| SCHEMBL29802097 | 0.93 | ACE (0.50) | ACERENOPRK1 | |
| SCHEMBL29802129 | 0.93 | ACE (0.52) | ACERENOPRK1 | |
| SCHEMBL30628782 | 0.92 | ACE (0.49) | ACERENOPRK1 | |
| SCHEMBL29801987 | 0.91 | ACE (0.52) | ACERENOPRK1 | |
| SCHEMBL29802427 | 0.91 | ACE (0.52) | ACERENOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665372-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | claimed |
| WO-2024169972-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-08-22 | — | — | WO | claimed |
| EP-4306534-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | Wuhan Innerse Pharmaceutical Inc. (CN) | 2024-01-17 | — | — | EP | claimed |
| US-20230348536-A1 | CONJUGATES OF MONTELUKAST AND PEPTIDES | ENLITISA SHANGHAI PHARMACEUTICAL CO LTD (CN) | 2023-11-02 | — | — | US | claimed |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | claimed |
| CN-116621924-A | Preparation method and application of tuna peptide for relieving chemotherapy-induced immune stress and intestinal mucosa injury | 南方海洋科学与工程广东省实验室(广州) | 2023-08-22 | — | — | CN | claimed |
| US-11680082-B2 | Conjugates of montelukast and peptides | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-06-20 | — | — | US | claimed |
| WO-2022188878-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | 武汉英纳氏药业有限公司 | 2022-09-15 | — | — | WO | claimed |
| EP-4665372-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250101063-A1 | POLYPEPTIDE COMPOUND AND USE THEREOF IN TREATMENT OF ENTERITIS | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-03-27 | — | — | US | disclosed |
| CN-116785447-B | Novel conjugates of montelukast and peptides | 艾缇亚(上海)制药有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024169972-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-08-22 | — | — | WO | disclosed |
| JP-2024509482-A | — | ウーハン イナース ファーマシューティカル インコーポレイテッド | 2024-03-01 | — | — | JP | disclosed |
| EP-4306534-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | Wuhan Innerse Pharmaceutical Inc. (CN) | 2024-01-17 | — | — | EP | disclosed |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
| CN-116785447-A | Novel conjugates of montelukast and peptides | 艾缇亚(上海)制药有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11680082-B2 | Conjugates of montelukast and peptides | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-06-20 | — | — | US | disclosed |
| CN-113121641-B | Multifunctional polypeptide and application thereof in medicine field | 武汉英纳氏药业有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022188878-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | 武汉英纳氏药业有限公司 | 2022-09-15 | — | — | WO | disclosed |
| WO-2022188878-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | 武汉英纳氏药业有限公司 | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348536-A1 | CONJUGATES OF MONTELUKAST AND PEPTIDES | IL33, HRH4, CYSLTR2 | ACE 2162/4885REN 1296/4885OPRK1 580/4885 |
| US-11680082-B2 | Conjugates of montelukast and peptides | IL33, HRH4, CYSLTR2 | ACE 2347/4885REN 1403/4885OPRK1 545/4885 |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | ACE 277/4885REN 197/4885OPRK1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.